Fortrea Holdings (FTRE) Amortization of Deferred Charges (2022 - 2026)
Fortrea Holdings (FTRE) posted Amortization of Deferred Charges of $2.0 million for Q1 2026, down 31.03% on a QoQ basis from $2.9 million in Q4 2025, and down 33.33% year-over-year from $3.0 million in Q1 2025.
Fortrea Holdings (FTRE) Amortization of Deferred Charges (2022 - 2026) Analysis & Trends
Fortrea Holdings' Amortization of Deferred Charges history runs 5 years deep, the most recent figure standing at $2.0 million for Q1 2026.
- Quarterly Amortization of Deferred Charges fell 33.33% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.5 million (down 2.78% YoY) and the FY2025 annual result came in at $11.5 million, down 17.86% from the prior year.
- Amortization of Deferred Charges was $2.0 million for Q1 2026 at Fortrea Holdings, down from $2.9 million in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $8.1 million in Q3 2022 and bottomed at -$1.1 million in Q3 2024.
- A 5-year average of $4.6 million and a median of $5.7 million in 2024 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2024 — Amortization of Deferred Charges plunged 116.67% — and 2025, when it surged 336.36%.
- Fortrea Holdings' Amortization of Deferred Charges stood at $5.9 million in 2022, then increased by 10.17% to $6.5 million in 2023, then tumbled by 50.77% to $3.2 million in 2024, then declined by 9.38% to $2.9 million in 2025, then tumbled by 31.03% to $2.0 million in 2026.
- Business Quant data shows FTRE's Amortization of Deferred Charges at $2.0 million in Q1 2026, $2.9 million in Q4 2025, and $2.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Fortrea Holdings | 1.83 Bn | 1.68 Bn | 123.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.00 Mn |
| Mar 31, 2026 | 2.00 Mn |
| Dec 31, 2025 | 2.90 Mn |
| Dec 31, 2025 | 2.90 Mn |
| Sep 30, 2025 | 2.60 Mn |
| Sep 30, 2025 | 2.60 Mn |
| Jun 30, 2025 | 3.00 Mn |
| Jun 30, 2025 | 3.00 Mn |
| Mar 31, 2025 | 3.00 Mn |
| Mar 31, 2025 | 3.00 Mn |
| Dec 31, 2024 | 3.20 Mn |
| Dec 31, 2024 | 3.20 Mn |
| Sep 30, 2024 | -1.10 Mn |
| Sep 30, 2024 | -1.10 Mn |
| Jun 30, 2024 | 5.70 Mn |
| Jun 30, 2024 | 5.70 Mn |
| Mar 31, 2024 | 6.20 Mn |
| Mar 31, 2024 | 6.20 Mn |
| Dec 31, 2023 | 6.50 Mn |
| Dec 31, 2023 | 6.50 Mn |